Research Topics
| Robert S McKelvieSummaryCountry: Canada Publications
| Collaborators
|
Detail Information
Publications
Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT)Robert S McKelvie
Division of Cardiology and Preventive Cardiology and Therapeutic Program, Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
Am Heart J 144:23-30. 2002..The purpose of this study was to examine the effects of exercise training on functional capacity in patients with heart failure...- Digoxin prescribing for heart failure in elderly residents of long-term care facilitiesBrian Misiaszek
Hamilton General Hospital, McMaster Clinic, Hamilton, Canada
Can J Cardiol 21:281-6. 2005..Studies are required to determine safe and effective digoxin dosing regimens for frail elderly heart failure patients. Clinicians should exercise caution when using digoxin in LTC residents... - Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or bothRaymond T Yan
The University Health Network, University of Toronto, Toronto, Ontario, Canada
Am J Cardiol 96:698-704. 2005..Serial measurements of these neurohormones may serve as useful surrogate markers of ventricular remodeling and prognosticators for clinical risk stratification... - Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failureCatherine Demers
McMaster University, Hamilton, Ontario, Canada
JAMA 294:1794-8. 2005..CONCLUSION: In patients with heart failure, candesartan significantly reduces the risk of the composite outcome of cardiovascular death or nonfatal MI... 
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failureRobert S McKelvie
Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
Can J Cardiol 29:168-81. 2013..The 2012 Update also includes recommendations, values and preferences, and practical tips to assist the medical practitioner manage their patients with HF...
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failureAndrew T Yan
Terrence Donnelly Heart Centre, Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
Eur J Heart Fail 10:125-8. 2008..There is also emerging preclinical information to suggest that these signalling pathways mutually regulate in HF...- Effect of aerobic vs combined aerobic-strength training on 1-year, post-cardiac rehabilitation outcomes in women after a cardiac eventHeather M Arthur
Department of Rehabilitation Medicine, McMaster University, Hamilton, ON, Canada
J Rehabil Med 39:730-5. 2007..To compare the effect and sustainability of 6 months combined aerobic/strength training vs aerobic training alone on quality of life in women after coronary artery by-pass graft surgery or myocardial infarction... - Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fractionJasmine Grewal
Population Health Research Institute and McMaster University, Hamilton, Ontario
Am J Cardiol 102:733-7. 2008..6 to 24.8, p = 0.0003) as was BNP >100 pg/ml (hazard ratio 3.1, 95% CI 1.2 to 8.2, p = 0.02) in the BNP model. In conclusion, both elevated NT-proBNP and BNP are strong independent predictors of clinical events in patients with HF-PLVEF... - Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failureAndrew T Yan
Heart and Stroke Richard Lewar Centre of Excellence, Toronto, Ontario, Canada
J Card Fail 12:514-9. 2006..We hypothesized that increased plasma MMP levels correlate with increased left ventricular (LV) volumes and reduced LV ejection fraction (LVEF) in patients with HF... - Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programmeRobert S McKelvie
HHSC General Division, Hamilton, Ontario, Canada
J Hypertens Suppl 24:S9-13. 2006..The use of angiotensin II receptor blockers may provide a means of fulfilling these needs... - ACE inhibitors in heart failure: what more do we need to know?Catherine Demers
Department of Medicine, Division of Cardiology, McMaster University, Hamilton, Ontario, Canada
Am J Cardiovasc Drugs 5:351-9. 2005..Although the use of ACE inhibitors may be appealing in patients with HF and preserved LV systolic function, there is currently no evidence from large clinical trials to support this... - The older patient with heart failure: high risk for frailty and cognitive impairmentKaren Harkness
Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
Expert Rev Cardiovasc Ther 10:779-95. 2012..Specifically, this article describes the epidemiology of these conditions in HF patients, outlines potential underlying mechanisms, highlights relevant screening tools and reviews relevant clinical implications... - Candesartan for the management of heart failure: more than an alternativeRobert S McKelvie
HHSC General Division, 237 Barton Street East, Hamilton, Ontario, L8L 2X2, Canada
Expert Opin Pharmacother 7:1945-56. 2006..This paper will review the data supporting the use of candesartan to treat all heart failure patients, regardless of their ejection fraction... - Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trialRobert S McKelvie
McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
J Card Fail 16:128-34. 2010..Less is known about NT-proBNP in HF with preserved EF (HF-PEF). We measured baseline NT-proBNP in 3562 HF-PEF enrolled patients in the Irbesartan in Heart Failure with Preserved Ejection Fraction trial... - Predicting heart failure mortality in frail seniors: comparing the NYHA functional classification with the Resident Assessment Instrument (RAI) 2.0Erin Y Tjam
St Mary s General Hospital, Kitchener, Ontario, Canada
Int J Cardiol 155:75-80. 2012..The purpose of this study was to determine whether a HF-specific prognostic model based on the RAI 2.0 is superior to the NYHA functional classification in predicting mortality in frail older HF patients... - Differences in sustainability of exercise and health-related quality of life outcomes following home or hospital-based cardiac rehabilitationKelly M Smith
McMaster University, Faculty of Health Sciences, Hamilton, Canada
Eur J Cardiovasc Prev Rehabil 11:313-9. 2004.... - The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failureRobert S McKelvie
Hamilton Health Sciences, Ontario, Canada
Expert Opin Investig Drugs 13:245-53. 2004..This paper reviews the data defining the role of ARBs in the treatment of HF patients, focusing more on the large randomised clinical outcome trials... - Management of heart failure in Canadian long-term care facilitiesGeorge A Heckman
McMaster University, Hamilton, Ontario, Canada
Can J Cardiol 20:963-9. 2004..In long-term care (LTC) facilities, heart failure is common but undertreated. No Canadian studies of heart failure in LTC facilities have been reported... - Exercise and the heart failure patient: aerobic vs strength training--is there a need for both?Elizabeth Gunn
McMaster University, Faculty of Health Sciences, Hamilton, Ontario, Canada
Prog Cardiovasc Nurs 21:146-50. 2006..Further research is required to isolate the specific role of strength training regarding improvements in prognosis, HF-related morbidity and hospitalization, and health-related quality of life for patients with HF... - The CHARM program: the effects of candesartan for the management of patients with chronic heart failureRobert S McKelvie
HHSC General Division, Ontario, Canada
Expert Rev Cardiovasc Ther 7:9-16. 2009..This paper will review the data supporting the use of candesartan to treat all HF patients, regardless of their ejection fraction... - Screening for cognitive deficits using the Montreal cognitive assessment tool in outpatients ≥65 years of age with heart failureKaren Harkness
Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
Am J Cardiol 107:1203-7. 2011..Future studies need to determine if the MoCA can identify the presence of CI that is predictive of adverse clinical outcomes in the HF population... - The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative careRobert S McKelvie
Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
Can J Cardiol 27:319-38. 2011..Furthermore, patients awaiting heart transplantation who deteriorate or are otherwise not likely to survive until a donor organ is found should be referred for MCS... - Heart failure and cognitive impairment: challenges and opportunitiesGeorge A Heckman
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Clin Interv Aging 2:209-18. 2007..Preliminary evidence suggests that optimal HF therapy in elderly patients may preserve or even improve cognitive function, though the impact on related outcomes remains to be determined... - Clinical, demographic and functional characteristics associated with pharmacotherapy for heart failure in older home care clients: a retrospective, population-level, cross-sectional studyAndrea D Foebel
Department of Health Studies Gerontology, University of Waterloo, Waterloo, Ontario, Canada
Drugs Aging 28:561-73. 2011..However, these first-line therapies are underused in older populations. This article describes the use and predictors of use of first-line HF therapies in a population-based cohort of older home care clients in Ontario, Canada... - Exercise training in patients with heart failure: clinical outcomes, safety, and indicationsRobert S McKelvie
Hamilton Health Sciences Corporation General Site, 237 Barton Street East, L8L 2X2, Hamilton, ON, Canada
Heart Fail Rev 13:3-11. 2008..This article reviews the effects of exercise training on clinical outcomes and addressing the safety of exercise training and the indications for training in HF patients... - Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failureRobert S McKelvie
Hamilton Health Sciences, General Division, Ontario, Hamilton, Canada
Eur Heart J 24:1727-34. 2003..Patients were later randomized to metoprolol CR (M) or placebo. Examine impact of C or E (C/E), C+E, C+M/E+M, C+E+M on ventricular remodelling in heart failure (HF) over 43 weeks... - Metabolic profile and exercise capacity outcomes: their relationship to overweight and obesity in a Canadian cardiac rehabilitation settingMamdouh M Shubair
Department of Medicine, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
J Cardiopulm Rehabil 24:405-13. 2004.... - Cardiovascular aging and exercise in healthy older adultsGeorge A Heckman
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Clin J Sport Med 18:479-85. 2008.... - Growth hormone therapy in heart failure: where are we now?Catherine Demers
Hamilton Health Sciences HHS, HHS General Division, Hamilton, Ontario, L8L 2X2 Canada
Congest Heart Fail 9:84-90. 2003..Despite the lack of benefit demonstrated in small, short-term, randomized clinical trials, further studies are needed to assess the potential role of this adjuvant therapy in heart failure patients... - Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: is BNP or NT-proBNP a useful assessment tool?Cynthia M Balion
Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada
Clin Biochem 41:266-76. 2008..We sought to determine whether B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) concentration changes occurred in parallel to changes in other measures of heart failure following treatment... - The impact of an outpatient heart failure clinic on hospital costs and admissionsSusan J Gregoroff
McMaster University, Hamilton Health Sciences-General Site, Hamilton, Ontario, Canada
Int J Health Care Qual Assur Inc Leadersh Health Serv 17:i-xi. 2004.... - The Dutch Objective Burden Inventory: validity and reliability in a Canadian population of caregivers for people with heart failureAnthony Makdessi
McMaster University, Hamilton, Ontario, Canada
Eur J Cardiovasc Nurs 10:234-40. 2011..Further testing is needed to determine floor and ceiling effects for DOBI items and responsiveness of this tool... - The role of angiotensin II receptor blockers in the treatment of heart failure patientsMichael Theal
Hamilton Health Sciences Corporation-General Division, McMaster University, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
Congest Heart Fail 9:29-34. 2003..The results from further studies are awaited to clarify the role of ARBs in the treatment of heart failure... - Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing)Daniel R Bensimhon
LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina, USA
Am J Cardiol 102:712-7. 2008..Therefore, in multicenter trials, there is no need to perform >1 baseline cardiopulmonary exercise test... - Growth hormone therapy in heart failure: a novel therapy worthy of further consideration?Catherine Demers
HHS General Division, Hamilton Ontario
Expert Opin Investig Drugs 14:1009-18. 2005..The randomised studies showing benefit consistently used growth hormone every other day. Further studies are needed to assess the potential role of this adjuvant therapy in patients with heart failure... - Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeEldrin Lewis
Department of Cardiology, Western Infirmary, Glasgow, Scotland G11 6NT, United Kingdom
Eur J Heart Fail 7:650-6. 2005..This benefit was obtained when candesartan was added to extensive background therapy and is consistent with the benefits of candesartan on NYHA class, hospital admission for worsening heart failure and mortality... - Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and managementJ Malcolm O Arnold
University of Western Ontario, London, Canada
Can J Cardiol 22:23-45. 2006..The goal is to translate best evidence-based therapies into clinical practice with a measureable impact on the health of heart failure patients in Canada... - Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trialsPhilip Jong
Heart and Stroke/Richard Lewar Centre of Excellence, Division of Cardiology, University Health Network, University of Toronto, Toronto, Canada
J Am Coll Cardiol 39:463-70. 2002..However, the use of ARBs as monotherapy in the absence of ACEIs or as combination therapy with ACEIs appears promising... - Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARMEldrin F Lewis
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Eur J Heart Fail 9:83-91. 2007..Limited comparative studies assessing the health-related quality of life (HRQL) in heart failure (HF) patients with preserved vs. low ejection fraction (LVEF) have been disparate... - Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkersJ Malcom O Arnold
University of Western Ontario, London, Canada
Can J Cardiol 23:21-45. 2007.... - Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMESHans Persson
Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital Department of Cardiology, Stockholm, Sweden
J Am Coll Cardiol 49:687-94. 2007..We tested the hypothesis that diastolic dysfunction (DD) was an important predictor of cardiovascular (CV) death or heart failure (HF) hospitalization in a subset of patients (ejection fraction [EF] >40%) in the CHARM-Preserved study... - The effects of exercise training on insulin resistance in patients with coronary artery diseaseNeville G Suskin
University of Western Ontario, London, ON, Canada
Eur J Cardiovasc Prev Rehabil 14:803-8. 2007..Moreover, patients with coronary artery disease (CAD) have not been studied... - Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practiceJohn McMurray
Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, UK
Eur J Heart Fail 7:710-21. 2005..These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines...